Clinical Trials on Neuroectodermal Tumors, Primitive, Peripheral in New Zealand

Total 1566 results

Children's Oncology Group
National Cancer Institute (NCI)

Completed

Collecting and Storing Biological Samples From Patients With Ewing Sarcoma

Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Askin Tumor

United States, Canada, Puerto Rico, Australia, New Zealand, Switzerland
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

Localized Extraskeletal Ewing Sarcoma | Peripheral Primitive Neuroectodermal Tumor of Bone | Peripheral Primitive Neuroectodermal Tumor of Soft Tissues

United States, Canada, Saudi Arabia, Australia, New Zealand, Puerto Rico
Pfizer

Terminated

Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib

Neuroblastoma

Australia, Korea, Republic of, United States, Portugal, New Zealand, Sweden
National Cancer Institute (NCI)

Active, not recruiting

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Ganglioneuroblastoma | High Risk Neuroblastoma

United States, New Zealand, Australia
Innervate Radiopharmaceuticals LLC (Formerly: Illumina...
Albert Einstein College of Medicine

Not yet recruiting

18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System

Neuroblastoma | Pheochromocytoma | Paraganglioma

United States
National Cancer Institute (NCI)

Completed

Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

Pineoblastoma | Recurrent Medulloblastoma | Refractory Medulloblastoma | Refractory Peripheral Primitive Neuroectodermal Tumor | Central Nervous System Neoplasm | Recurrent Primitive Neuroectodermal Tumor

United States, Canada, Puerto Rico, Australia, New Zealand
Jubilant DraxImage Inc.

Recruiting

A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects (OPTIMUM)

Neoplasms | Neuroectodermal Tumors | Neuroblastoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Primitive Neuroectodermal Tumors

Brain and Central Nervous System Tumors | Neuroblastoma

United States
Northwell Health
Cohen Children's Medical Center

Available

A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma

Neuroblastoma | Pheochromocytoma

United States
Memorial Sloan Kettering Cancer Center
Washington University School of Medicine; Weill Medical College of Cornell... and other collaborators

Recruiting

Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Active, not recruiting

Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics; Band of Parents

Completed

Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center

Completed

Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Completed

Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center

Terminated

3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center

Completed

3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow

Neuroblastoma

United States
Columbia University

Terminated

Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Active, not recruiting

Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center

Completed

High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation

Neuroblastoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

Medulloblastoma | Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor | Anaplastic Medulloblastoma | Supratentorial Embryonal Tumor, Not Otherwise Specified

United States, Canada, Australia, Puerto Rico
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Active, not recruiting

A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center

Completed

Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center

Completed

3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma

Neuroblastoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors

Recurrent Ewing Sarcoma | Recurrent Childhood Rhabdomyosarcoma | Previously Treated Childhood Rhabdomyosarcoma | Recurrent Childhood Soft Tissue Sarcoma | Peripheral Primitive Neuroectodermal Tumor

United States, Canada
GE Healthcare

Approved for marketing

Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma

Neuroblastoma

United States
National Cancer Institute (NCI)

Completed

Fenretinide in Treating Children With Solid Tumors

Unspecified Childhood Solid Tumor, Protocol Specific | Neuroblastoma

United States, Australia
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of N9 Chemotherapy in Children With Neuroblastoma

Neuroblastoma | Pediatric Cancer

United States
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Active, not recruiting

PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study

Melanoma | Sarcoma | Neuroblastoma

United States
Eli Lilly and Company

Recruiting

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Relapsed Solid Tumor | Refractory Solid Tumor

United States, Canada, Australia, Belgium, France, Spain, Germany, Italy
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Active, not recruiting

Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

Neuroblastoma | High-Risk

United States
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Active, not recruiting

Study of Chemoimmunotherapy for High-Risk Neuroblastoma

Neuroblastoma (NB)

United States
Novartis Pharmaceuticals

Terminated

Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma

Neuroblastoma | Malignant Rhabdoid Tumors (MRT)

France, Germany, United Kingdom, United States, Australia
GE Healthcare

Completed

Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma

Neuroblastoma | Pheochromocytoma

United States
Memorial Sloan Kettering Cancer Center

No longer available

Naxitamab and GM-CSF in People With Neuroblastoma

High-Risk Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center

Completed

Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy Plus Etoposide in Treating Patients With Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center

Completed

Monoclonal Antibody Therapy in Treating Children With Metastatic Neuroblastoma in Second Remission

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Multiple Therapies in Treating Patients With Advanced Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment

Neuroblastoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

Neuroblastoma | Ganglioneuroblastoma, Nodular

United States, Australia, Canada, New Zealand
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma

Neuroblastoma

United States, Canada, Australia, Puerto Rico, New Zealand, Netherlands
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Children With Neuroblastoma

Neuroblastoma

United States, Canada, Australia, Switzerland, Puerto Rico, Netherlands, New Zealand
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center

Completed

Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma

Neuroblastoma

United States

Clinical Trials on Neuroectodermal Tumors, Primitive, Peripheral in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations